Results 201 to 210 of about 145,148 (243)
Some of the next articles are maybe not open access.
Plasma cell leukemia in pregnancy
Blood, 2012![Figure][1] A 35-year-old multigravida with a 24-week pregnancy presented with generalized weakness and altered sensorium for 2 weeks. Physical examination revealed pallor and an enlarged uterus corresponding to gestational age.
Bushra, Moiz, Syed Sarwar, Ali
exaly +3 more sources
Plasma cell leukemia with myelofibrosis
Annals of Hematology, 1994We describe a case of plasma cell leukemia associated with myelofibrosis. A 60-year-old woman was admitted due to lumbago and monoclonal hypergammaglobulinemia. Peripheral blood showed about 40% of plasma-cell-like cells. A bone marrow aspiration was dry tap.
Murayama T, Isobe T, Matsui T
exaly +3 more sources
Current Treatment Options in Oncology, 2001
Plasma cell leukemia (PCL) is a rare aggressive variant of multiple myeloma (MM) characterized by a fulminant course and poor prognosis. The median survival is measured in months. Therapy and prognosis partially depend on whether the disease presents de novo or as a secondary process involving the leukemic transformation of a previously diagnosed MM ...
S R, Hayman, R, Fonseca
openaire +2 more sources
Plasma cell leukemia (PCL) is a rare aggressive variant of multiple myeloma (MM) characterized by a fulminant course and poor prognosis. The median survival is measured in months. Therapy and prognosis partially depend on whether the disease presents de novo or as a secondary process involving the leukemic transformation of a previously diagnosed MM ...
S R, Hayman, R, Fonseca
openaire +2 more sources
Plasmacytomas and Plasma-Cell Leukemia
New England Journal of Medicine, 2017A 63-year-old man with multiple myeloma who had received extensive treatment for the condition presented with lesions on his arms and chest wall. Biopsy revealed plasmacytomas. Peripheral-blood smear revealed 25% plasma cells.
Uqba, Khan, Tarik, Hadid
openaire +2 more sources
Bortezomib and Plasma Cell Leukemia.
Blood, 2006Abstract Bortezomib (Velcade) is currently approved in USA and EU for the treatment of resistant/relapsed multiple mieloma (MM). Some reports have suggested that bortezomib is particularly effective for the treatment of extramedullary MM. However, there are very few data about the efficacy of this drug in plasma cell leukemia (PCL), a MM
Pellegrino Musto +15 more
openaire +1 more source
Leukemia & Lymphoma, 2007
Plasma cell leukemia represents a unique subset of patients with multiple myeloma. The definition requires that: (i) for a blood leukocyte count of >10 000/µl, at least 2000/µl are circulating plas...
openaire +2 more sources
Plasma cell leukemia represents a unique subset of patients with multiple myeloma. The definition requires that: (i) for a blood leukocyte count of >10 000/µl, at least 2000/µl are circulating plas...
openaire +2 more sources
Plasma cell dyscrasias and leukemias
Update on Cancer Therapeutics, 2005Abstract There has been remarkable progress in our understanding of plasma cell dyscrasias and leukemias in recent years. New prognostic factors have come to light. Del(1)(p12) and t(4;14) confer poor prognoses on patients with myeloma. COX-2 positivity is associated with poorer progression-free and overall survival in myeloma patients and a role for
openaire +2 more sources
2017
Primary plasma cell leukemia (pPCL) is a de novo presentation of an aggressive extramedullary myeloma characterized by circulating plasma cells in peripheral blood. The clonal plasma cells may accumulate genetic aberrations rapidly in a very short period, resulting in de novo pPCL (from monoclonal gammopathy of undetermined significance to pPCL ...
Nisha S. Joseph +2 more
openaire +2 more sources
Primary plasma cell leukemia (pPCL) is a de novo presentation of an aggressive extramedullary myeloma characterized by circulating plasma cells in peripheral blood. The clonal plasma cells may accumulate genetic aberrations rapidly in a very short period, resulting in de novo pPCL (from monoclonal gammopathy of undetermined significance to pPCL ...
Nisha S. Joseph +2 more
openaire +2 more sources
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1989
The following article describes five patients with plasma cell leukemia treated during the last two years at a Medical University Polyclinic. Plasma cell leukemia is a disease which was seen extremely rarely in the past. The disease can develop in patients with multiple myeloma or, even more rarely, as a "de novo" disease.
F, Egli, K, Rhyner
openaire +1 more source
The following article describes five patients with plasma cell leukemia treated during the last two years at a Medical University Polyclinic. Plasma cell leukemia is a disease which was seen extremely rarely in the past. The disease can develop in patients with multiple myeloma or, even more rarely, as a "de novo" disease.
F, Egli, K, Rhyner
openaire +1 more source
Bulletin du cancer, 2015
Plasma cell leukemia (PCL) is a rare disorder which develops spontaneously (primary PCL) or evolves in patients with multiple myeloma (secondary PCL). It is defined by the presence of 2 × 10(9)/L peripheral blood plasma cells or plasmacytosis accounting for more than 20 % of the differential white cell count.
Aurélie, Ravinet +2 more
openaire +1 more source
Plasma cell leukemia (PCL) is a rare disorder which develops spontaneously (primary PCL) or evolves in patients with multiple myeloma (secondary PCL). It is defined by the presence of 2 × 10(9)/L peripheral blood plasma cells or plasmacytosis accounting for more than 20 % of the differential white cell count.
Aurélie, Ravinet +2 more
openaire +1 more source